Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

Enrolling by invitation

Conditions studied: Medullary Thyroid Carcinoma

In brief

This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.

Key facts

Study ID

NCT07713901

Run by

Novo Nordisk A/S

People needed

93600000

Starts

2025-12-31

Expected to finish

2026-12-31

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older during the year of index (date of qualifying medication)
• In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1
• ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)
• No evidence of cohort qualifying medication during 12-month before the index date
• Reside in the US, including the District of Columbia (DC) during the study period
• No missing values for year of birth

You may not qualify if…

• Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.

Where it is running

• IQVIA — Parsippany, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.